Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma

Urology

Volumn 62, Issue 2, 2003, Pages 368-373

  Bamias, Aristotle ^a   Chorti, M ^a   Deliveliotis, C ^a   Trakas, N ^a   Skolarikos, A ^a   Protogerou, B ^a   Legaki, S ^a   Tsakalou, G ^a   Tamvakis, N ^a   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CELL ADHESION MOLECULE; EPITHELIAL MEMBRANE ANTIGEN; HERMES ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHRECTOMY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 0042623891     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00264-4     Document Type: Article

References (30)

1. Eble N. Neoplasms of the kidney. Bostwick D.G., Eble J.N. Urologic Surgical Pathology. 1997;83-147 Mosby, New York.
2. Sternberg S.S. Diagnostic Surgical Pathology. 3rd ed:1999;Mosby, St. Louis.
3. Rioux-Leclercq N., Turlin B., Bansard J., et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 55:2000;501-505.
4. de la Taille A., Buttyan R., Katz A.E., et al. Biomarkers of renal cell carcinoma past and future considerations . Urol Oncol. 5:2000;139-148.
5. Lee J.S., Kim H.S., Jung J.J., et al. Statement of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein statement. J Surg Oncol. 77:2000;55-60.
6. Kuroiwa K., Konomoto T., Kumazawa J., et al. Cell proliferative activity and statement of cell-cell adhesion factors (E-cadherin, alpha-, beta-, and gamma-catenin, and p120) in sarcomatoid renal cell carcinoma. J Surg Oncol. 77:2001;123-131.
7. Yoshino S., Kato M., Okada K. Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. Anticancer Res. 20:2000;591-594.
8. Grankvist K., Ljungberg B., Rasmuson T. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA19-9, CA-125, CA 15-3) for the prognosis of renal cell carcinoma. Int J Cancer. 74:1997;233-236.
9. Ljungberg B., Rasmuson T., Grankvist K. Erythropoietin in renal cell carcinoma evaluation of its usefulness as a tumor marker . Eur Urol. 21:1992;160-163.
10. Dexeus F.H., Logothetis C.J., Sella A., et al. Serum biomarkers in metastatic renal cell carcinoma. Urology. 38:1991;6-10.
11. Bremster S.F., Oxley J.D., Trivella M., et al. Preoperative p53, bcl2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 161:1999;1238-1243.
12. Tran T.A., Kalakury M.D., Sheehan C.E., et al. statement of CD44 standard form and variant isoforms in non small cell carcinomas. Hum Pathol. 28:1997;809-814.
13. Stauder R., Eisterer W., Thaler J., et al. CD44 variant isoforms in non-Hodgkin's lymphoma a new independent prognostic factor . Blood. 85:1999;2885-2899.
14. Lipponen P., Aaltonna S., Kosma V.M., et al. Statement of CD44 standard and variant v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol. 186:1998;157-164.
15. Bottger T.C., Youssef V., Dutkowski P., et al. Statement of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis. Cancer. 83:1998;1074-1080.
16. De Marzo A.M., Bradshaw C., Sauvageot J., et al. CD44 and CD44v6 downregulation to Gleason grade and cytoarchitecture. Prostate. 34:1998;162-168.
17. Paradis V., Ferlicot S., Ghannam E., et al. CD44 is an independent prognostic factor in conventional renal cell carcinomas. J Urol. 161:1999;1984-1987.
18. Bast R.C. Jr, Xu F.J., Yu Y.H., et al. CA 125 the past and the future . Int J Biol Markers. 13:1998;179-187.
19. Ammon A., Weber M.H., Wallner I., et al. Expression of the tumor-associated glycoproteins MCA, CA 125 and BW 495/36-P in epithelial tumours of the kidney and the urinary bladder. Int J Biol Markers. 9:1994;224-230.
20. Ammon A., Weber M.H., Wallner I., et al. Immunocytochemical determination of the tumour-associated glycoproteins MCA, CA 125 and BW 495/36-P in urine of patients with epithelial tumours of the kidney and the urinary bladder. Int J Biol Markers. 10:1995;17-23.
21. Li G., Passeboc-Faure K., Lambert C., et al. Flow cytometric analysis of antigen expression in malignant and normal renal cells. Anticancer Res. 20:2000;2273-2278.
22. Rosay J. Special techniques in surgical pathology. Patterson N.S. Ackermann's Surgical Pathology. 1996;29-62 Mosby, New York.
23. Madeiros L.J., Michie S.A., Johnson D.E., et al. An immunoperoxidase study of renal cell carcinomas correlation with nuclear grade, cell type, and histologic pattern . Hum Pathol. 19:1988;980-987.
24. Sabo E., Miselevich I., Bejar J., et al. The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br J Urol. 80:1997;864-868.
25. Brauers A., Effert P., Siefert C., et al. Prognostic relevance of immunohistochemical parameters in renal cell carcinoma. J Urol. 155:1996;344A. (abstract).
26. Tran T.A., Bhaskar V.S., Kallakury V.S., et al. Expression of CD44 standard and variant isoforms in non-small cell lung carcinomas. Hum Pathol. 28:1997;809-814.
27. Terpe H.J., Storkel S., Zimmer U., et al. Expression of CD44 isoforms in renal cell tumors positive correlation to tumor differentiation . Am J Pathol. 148:1996;453-463.
28. Gilcrease M.Z., Guzman-Paz M., Niehans G., et al. Correlation of CD44s expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer. 86:1999;2320-2326.
29. Heider K.H., Hofmann M., Hors E., et al. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol. 120:1993;227-233.
30. Kuppner M.C., van Meir E., Gauthier T., et al. Differential expression of the CD44 molecule in human brain tumours. Int J Cancer. 50:1992;572-577.